BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:With 2023 welcoming newly FDA-approved gene therapies from Bio
 Marin\, Krystal Biotech and Sarepta Therapeutics\, many more treatments a
 re hot on their heels for approval\, investment is pouring into developin
 g gene therapies and the role of regulatory affairs has never been more i
 mportant.\n\nAs the first ever regulatory affairs forum wholly dedicated 
 to gene therapy\, this meeting uniquely unites regulatory bodies and the 
 leading regulatory personnel across big pharma and innovative biotech to 
 discuss the hottest topics\, identify industry bottlenecks and offer acti
 onable insights.\n\nDon't miss out on this unrivalled opportunity to info
 rm your trial design\, perfect your CMC approach and supercharge your glo
 bal submission strategy for regulatory success.\n\nJoin 80+ industry lead
 ers from 4D Molecular Therapeutics\, Advanced Cell and Gene Therapy\, Adv
 erum Biotechnologies\, Astrazeneca\, Bridge Bio\, Health Canada\, Omega T
 herapeutics\, Opus Genetics\, Regeneron Pharmaceuticals\, Sangamo Therape
 utics\, Solid Biosciences\, Spark Therapeutics\, Ultragenyx Pharmaceutica
 l\, and more...\n\nURLs:Tickets:&nbsp\;https://go.evvnt.com/1970410-2?pid
 =185Brochure:&nbsp\;https://go.evvnt.com/1970410-3?pid=185\n\nPrices:Drug
  Developer Pricing - Conference + Workshop Day: USD 4297.00\,Drug Develop
 er Pricing - Conference Only: USD 2999.00\,Service Provider Pricing - Con
 ference + Workshop Day: USD 5297.00\,Service Provider Pricing - Conferenc
 e Only: USD 3799.00\,Academic Pricing - Conference + Workshop Day: USD 36
 97.00\,Academic Pricing - Conference Only: USD 2599.00\n\nSpeakers:&nbsp\
 ;Anastasia Yemelyanova\, Regulatory Affairs CMC Lead\, Spark Therapeutics
 \, Brian Baker\, Senior Director of IVD Regulatory Affairs\, Regeneron Ph
 armaceuticals\, Catherine Campbell\, Vice President of Regulatory Affairs
  and Quality Assurance\, Deirdre Harwood\, Senior Director of Regulatory 
 Affairs\, Ultragenyx Pharmaceutical\, Dunni Odumosu\, Vice President of G
 lobal Regulatory Affairs\, Bridge Bioscience Corp\, Jim Wang\, Chief Regu
 latory Officer\, Adverum\, Maria Lobikin\, Director\, Regulatory CMC\, So
 lid Biosciences\, Natalia Shunmugan\, Senior Director of Global Regulator
 y Intelligence and Policy\, Ultragenyx\, Omar Tounekti\, Manager\, Health
  Canada\, Q. Melody Dai\, Senior Director of Regulatory Affairs\, Adverum
  Biotechnologies\, Sarah Tuller\, Vice President and Chief Regulatory Off
 icer\, Opus Genetics\, Inc\, Saumyaa Saumyaa\, Associate Director\, Astra
 Zeneca\, Scott Burger\, Principal\, Advanced Cell and Gene Therapy\, Sian
 na Castillo\, Senior Director\, Sangamo Therapeutics\, Suman Jangid\, Ass
 ociate Director - Global Regulatory CMC - Novel Gene Therapy\, Omega Ther
 apeutics\, Inc.\, Thomas Powers\, Senior Principal Scientist and Group Le
 ader\, Pfizer\, Yao-Yao Zhu\, Director of Global Regulatory Affairs\, Ast
 raZeneca\n\nCategory:&nbsp\;Conferences | Science\, Health and Medicine\n
 \nDate and Time:&nbsp\;23rd January 2024 at 9:00 am to 25th January 2024 
 at 3:30 pm\n
DTEND:20240125T153000
DTSTAMP:20260416T134013Z
DTSTART:20240123T090000
LOCATION:Boston Park Plaza\, 50\, Park Plaza\, Boston\, Massachusetts\, 02
 116\,
SEQUENCE:0
SUMMARY:With 2023 welcoming newly FDA-approved gene therapies from BioMari
 n\, Krystal Biotech and Sarepta Therapeutics\, many more treatments are h
 ot on thei...
UID:675f9bdd-12b0-46ce-b8ac-50021ea27449
END:VEVENT
END:VCALENDAR